Published in Pediatr Infect Dis J on October 01, 2010
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir Ther (2011) 1.02
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother (2012) 0.95
Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res (2014) 0.93
Formulations for children: problems and solutions. Br J Clin Pharmacol (2015) 0.87
Managing HIV-infected children in a low-resource, public clinic: a comparison of nurse vs. clinical officer practices in ART refill, calculation of adherence and subsequent appointments. J Int AIDS Soc (2012) 0.79
Evaluation of nevirapine dosing recommendations in HIV-infected children. Br J Clin Pharmacol (2013) 0.77
Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol (2011) 0.76
The Need for Pediatric Formulations to Treat Children with HIV. AIDS Res Treat (2016) 0.75
Dose evaluation of lamivudine in HIV-infected children aged 5 months-18 years based on a population pharmacokinetic analysis. Br J Clin Pharmacol (2017) 0.75
Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children. J Virus Erad (2015) 0.75
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother (2016) 0.75
Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects. Arch Dis Child (2016) 0.75
Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. PLoS One (2017) 0.75
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis (2005) 2.44
Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet (1999) 2.40
In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS (2006) 2.11
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit (2003) 1.71
Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses (2002) 1.66
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS (2005) 1.66
Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit (2006) 1.53
Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J (2007) 1.44
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet (2003) 1.43
2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis (1993) 1.37
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS (2008) 1.36
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS (2007) 1.26
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis (1996) 1.12
Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother (2005) 1.11
Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV. Clin Pharmacokinet (2001) 1.11
Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther (2007) 1.10
Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection. Antimicrob Agents Chemother (2001) 0.99
Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis (2008) 0.99
Nevirapine use in HIV-1-infected children. AIDS (2003) 0.99
Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less. Pediatr Infect Dis J (2009) 0.95
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr (2006) 0.92
Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med (2008) 10.27
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med (2010) 9.90
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med (2004) 6.48
Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol (2003) 5.43
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med (2015) 4.79
Reduced lopinavir exposure during pregnancy. AIDS (2006) 3.98
Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics (2004) 3.71
Influenza A H5N1 replication sites in humans. Emerg Infect Dis (2005) 3.21
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis (2008) 3.09
Transparent development of the WHO rapid advice guidelines. PLoS Med (2007) 2.57
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis (2005) 2.44
Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis (2007) 2.39
Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS (2008) 2.35
A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet (2005) 2.31
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J (2009) 2.14
What strategies to boost production of affordable fixed-dose anti-retroviral drug combinations for children in the developing world? Curr HIV Res (2007) 2.12
Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics (2002) 2.08
Evaluation of an NS1 antigen detection for diagnosis of acute dengue infection in patients with acute febrile illness. Diagn Microbiol Infect Dis (2008) 2.06
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol (2008) 1.96
Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. Drug Metab Dispos (2009) 1.95
Disclosure of HIV/AIDS diagnosis to HIV-infected children in Thailand. J Paediatr Child Health (2006) 1.93
Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA (2005) 1.91
Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS (2014) 1.91
Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet (2004) 1.86
WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis (2007) 1.85
Avian influenza virus infection of children in Vietnam and Thailand. Pediatr Infect Dis J (2004) 1.83
A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics (2006) 1.78
Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J (2006) 1.76
Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol (2012) 1.74
Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis (2007) 1.72
Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis (2005) 1.70
Cohort profile: the TREAT Asia pediatric HIV observational database. Int J Epidemiol (2010) 1.70
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr (2005) 1.69
Early immunological predictors of neurodevelopmental outcomes in HIV-infected children. Clin Infect Dis (2009) 1.68
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis (2004) 1.67
Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis (2010) 1.66
Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis (2011) 1.66
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS (2005) 1.66
Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr (2008) 1.65
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis (2010) 1.64
Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis (2006) 1.64
Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis (2008) 1.60
Aerosol transmission is an important mode of influenza A virus spread. Nat Commun (2013) 1.56
Evaluating programs to prevent mother-to-child HIV transmission in two large Bangkok hospitals, 1999-2001. J Acquir Immune Defic Syndr (2005) 1.54
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS (2007) 1.53
Reduced mother-to-child transmission of HIV associated with infant but not maternal GB virus C infection. J Infect Dis (2008) 1.53
Planned multiple exposures to autologous virus in HIV type 1-infected pediatric populations increases HIV-specific immunity and reduces HIV viremia. AIDS Res Hum Retroviruses (2008) 1.52
Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J (2007) 1.44
Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection. Clin Infect Dis (2004) 1.44
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother (2008) 1.44
Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. Pediatrics (2006) 1.42
A novel mutation of the CYBB gene resulting in severe form of X-linked chronic granulomatous disease. Asian Pac J Allergy Immunol (2007) 1.41
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J (2007) 1.39
Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics (2005) 1.39
Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS (2012) 1.39
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J (2005) 1.34
Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2015) 1.33
Clinical performance of a rapid influenza test and comparison of nasal versus throat swabs to detect 2009 pandemic influenza A (H1N1) infection in Thai children. Pediatr Infect Dis J (2010) 1.32
Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J (2009) 1.32
Detection of dengue virus in platelets isolated from dengue patients. Southeast Asian J Trop Med Public Health (2009) 1.29
Human bocavirus: developing evidence for pathogenicity. J Infect Dis (2006) 1.28
Six year multicenter surveillance of invasive pneumococcal infections in children. Pediatr Infect Dis J (2002) 1.28
In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS (2011) 1.26
Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav (2010) 1.26
Virologic response to potent antiretroviral therapy and modeling of HIV dynamics in early pediatric infection. J Infect Dis (2007) 1.26
Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. J Acquir Immune Defic Syndr (2010) 1.25
Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med (2002) 1.25
History and recent advances in coronavirus discovery. Pediatr Infect Dis J (2005) 1.24
Survival of HIV-infected children: a cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr (2011) 1.24
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine (2008) 1.23
Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children. AIDS Res Ther (2011) 1.22
Poor cognitive functioning of school-aged children in thailand with perinatally acquired HIV infection taking antiretroviral therapy. AIDS Patient Care STDS (2010) 1.21
Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J (2009) 1.20
Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (2011) 1.20
Coronaviruses in the limelight. J Infect Dis (2005) 1.20
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand. PLoS Med (2013) 1.20
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther (2007) 1.18
Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis (2005) 1.18
Predictors of immunologic long-term nonprogression in HIV-infected children: implications for initiating therapy. J Allergy Clin Immunol (2005) 1.18
Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand. J Acquir Immune Defic Syndr (2012) 1.18
The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antiviral Res (2007) 1.17
HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS (2006) 1.15
Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med (2011) 1.14
Streptococcus pneumoniae infections in the neonate. Pediatrics (2003) 1.14